



Benjamin Weide

Kontakt

Benjamin Weide

Publikationen (9)

Gaessler A, Boehm J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. *J Immunother Cancer* 2023; 11

Gaessler A, Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Boehm J, Spreuer J, Amaral T, Wagner N, Klein R, Meier F, Garbe C, Eigentler T, Pawelec G, Claassen M, Weide B, Hadrup S, Wistuba-Hamprecht K. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. *Front Immunol* 2022; 13:906352.

Gassenmaier M, Lenders M, Forschner A, Leiter U, Weide B, Garbe C, Eigentler T, Wagner N. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. *Target Oncol* 2021; 16:197-205.

Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. *J Immunother Cancer* 2021; 9

Boehm J, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler T, Löffler M, Weide B, Niessner H, Sinnberg T, Zelba H, Spreuer J, Amaral T, Gaessler A, Pop O, Thiel K, Yurttas C, Soffel D, Forchhammer S, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. *J Immunother Cancer* 2021; 9

Winter J, Eigentler T, Garbe C, Röcken M, Cozzio A, Flatz L, Purde M, Weide B, Leiter U, Forschner A, Gassenmaier M, Lenders M, Wagner N. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. *Cancer Immunol Immunother* 2020; 70:1089-1099.

Wagner N, Utikal J, Umansky V, Garbe C, Schadendorf D, Holland-Letz T, Herpel E, Sucker A, Lichtenberger R, Funder A, Kehrel C, Kemper C, Schuermans V, Tarnanidis K, Reith M, Gries M, Weide B, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. *J Immunother Cancer* 2019; 7:343.

Boehm J, Weide B, Pawelec G, Garbe C, Meier F, Terheyden P, Uslu U, Wagner N, Eigentler T, Soffel D, Spreuer J, Amaral T, Zelba H, Wistuba-Hamprecht K. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. *PloS one* 2019; 14:e0221301.

Wagner N, Utikal J, Enk A, Umansky V, Garbe C, Naeher H, Holland-Letz T, Busch C, Ikenberg K, Eubel J, Herpel E, Pflugfelder A, Lichtenberger R, Kehrel C, Tarnanidis K, Reith M, Weide B, Gebhardt C. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. *Int J Cancer* 2015; 137:2607-17.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch